Minerva Neurosciences (NASDAQ:NERV) Announces Quarterly Earnings Results, Beats Estimates By $0.49 EPS

Minerva Neurosciences (NASDAQ:NERV) posted its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.49, Zacks reports.

Minerva Neurosciences Price Performance

Shares of NERV stock opened at $1.73 on Tuesday. Minerva Neurosciences has a 1 year low of $1.77 and a 1 year high of $7.53. The company has a market cap of $12.10 million, a PE ratio of -3.95 and a beta of 0.12. The stock’s 50 day simple moving average is $2.18 and its two-hundred day simple moving average is $2.40.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on NERV shares. HC Wainwright reiterated a “neutral” rating and set a $5.00 target price on shares of Minerva Neurosciences in a research report on Wednesday, November 6th. StockNews.com initiated coverage on shares of Minerva Neurosciences in a report on Saturday. They set a “sell” rating for the company.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.